AAPL 222.42 0.1306% MSFT 379.9748 1.2213% NVDA 108.0843 -0.2728% GOOGL 156.98 1.5132% GOOG 158.72 1.5938% AMZN 190.79 0.2786% META 581.285 0.8545% AVGO 164.84 -1.5469% LLY 815.72 -1.2338% TSLA 271.0582 4.5911% TSM 167.21 0.7289% V 348.675 -0.5093% JPM 243.405 -0.7725% UNH 524.6606 0.1739% NVO 69.62 0.2592% WMT 88.5515 0.8674% LVMUY 124.02 -1.945% XOM 118.56 -0.3111% LVMHF 621.65 -1.8791% MA 548.27 0.0274%
AAPL 222.42 0.1306% MSFT 379.9748 1.2213% NVDA 108.0843 -0.2728% GOOGL 156.98 1.5132% GOOG 158.72 1.5938% AMZN 190.79 0.2786% META 581.285 0.8545% AVGO 164.84 -1.5469% LLY 815.72 -1.2338% TSLA 271.0582 4.5911% TSM 167.21 0.7289% V 348.675 -0.5093% JPM 243.405 -0.7725% UNH 524.6606 0.1739% NVO 69.62 0.2592% WMT 88.5515 0.8674% LVMUY 124.02 -1.945% XOM 118.56 -0.3111% LVMHF 621.65 -1.8791% MA 548.27 0.0274%

small-cap

One NASDAQ - Listed Biotechnology Stock Under Radar- SNSE

Mar 28, 2025 | Team Kalkine
One NASDAQ - Listed Biotechnology Stock Under Radar- SNSE
Image source: Shutterstock

SNSE:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Sensei Biotherapeutics, Inc (NASDAQ: SNSE)

Sensei Biotherapeutics, Inc (NASDAQ: SNSE) is a clinical-stage immuno-oncology company dedicated to developing cancer therapeutics. Utilizing its Tumor Microenvironment Activated biologics (TMAb) platform, the company designs conditionally active treatments that either block immunosuppressive signals or enhance immunostimulatory signals specifically within the tumor microenvironment, aiming to activate T cells against cancer.

Positive Growth Prospects

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.